Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Weight loss medications stories

Oct 13, 2026

New trial to examine GLP-1 drugs' impact on criminal justice interactions, employment and housing

A newly announced clinical trial will test whether GLP-1 weight loss drugs can improve outcomes related to criminal justice system interactions, employment, and housing stability, expanding beyond existing trials examining the medications' effects on substance use disorders and other health conditions.

Oct 13, 2026·4 sources
00
Sep 8, 2026

GLP-1 drugs linked to reduced asthma and COPD attacks in new studies

New research shows that GLP-1 receptor agonists like semaglutide, commonly used for weight loss and diabetes treatment, are associated with fewer exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The findings are based on real-world patient data and add to growing evidence of respiratory benefits from these medications.

Sep 8, 2026·3 sources
00
Aug 10, 2026

UK becomes first European country to approve Eli Lilly's once-daily weight loss pill Foundayo

The UK's Medicines and Healthcare products Regulatory Agency has authorized orforglipron (brand name Foundayo), a once-daily oral medication from Eli Lilly for treating obesity and type 2 diabetes, making the UK the first country in Europe to approve the drug.

Aug 10, 2026·6 sources
00
Jul 30, 2026

Study examines potential link between GLP-1 drugs and temporary hair loss

New research suggests that GLP-1 medications like Ozempic and Wegovy may increase the risk of temporary hair loss, though the overall risk appears to be low.

Jul 30, 2026·1 source
00
May 3, 2026

GLP-1 Drugs Taken Around Pregnancy Show No Increased Risk of Birth Defects in New Study

University of St Andrews study published in American Journal of Obstetrics suggests weight-loss drugs like Ozempic taken around pregnancy do not raise the risk of major birth defects.

May 3, 2026·1 source
00

Top claims

  • ▪Research presented at the European Respiratory Society Congress linked GLP-1 medications to reduced asthma attacks and chronic obstructive pulmonary disease flare-ups.
  • ▪A clinical trial published in the New England Journal of Medicine showed 62.9% of metabolic dysfunction-associated steatohepatitis patients taking semaglutide achieved disease resolution without worsening liver fibrosis, compared with 34.3% taking placebo.
  • ▪A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.

Subtopics

Lifestyle, Wellness and Nutrition4Weight loss medications & GLP-1 drugs4GLP-1 medications3GLP-1 drugs2Clinical trials1Criminal justice reform1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1GLP-1 / Weight-Loss Medications1GLP-1 receptor agonists1Healthcare Policy1Obesity treatment1Pharma1Pregnancy & maternal health1Pregnancy health1Reproductive Health1Respiratory health1Substance use disorder1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories